| Dr Mohammed Y Sandhu, MD | |
|
672 Broadway, Bayonne, NJ 07002-4725 | |
| (201) 339-3710 | |
| Not Available |
| Full Name | Dr Mohammed Y Sandhu |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 54 Years |
| Location | 672 Broadway, Bayonne, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568405702 | NPI | - | NPPES |
| 3019900 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MA31401 (New Jersey) | Primary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MA31401 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayonne Medical Center | Bayonne, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Essex Hudson Cardiology Associates Llp | 0042374092 | 4 |
News Archive
A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
President Barack Obama and House Speaker John Boehner each delivered prime time addresses Monday night, capping an extraordinary day of partisan debt-ceiling dueling. As the clock continues to tick toward the Aug. 2 deadline, specifics from the two very different plans emerged — one offered by House Republicans and the other by Senate Democrats.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
California is the bright spot in enrolling people in the health law's insurance exchanges - beating even the federal Healthcare.gov in how many have signed up. Still, California's enrollment figures - representing about a third of all signups around the nation - mean less than 1 percent of uninsured Californians have signed up for plans.
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
› Verified 8 days ago
| Entity Name | Essex Hudson Cardiology Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457490310 PECOS PAC ID: 0042374092 Enrollment ID: O20090205000593 |
News Archive
A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
President Barack Obama and House Speaker John Boehner each delivered prime time addresses Monday night, capping an extraordinary day of partisan debt-ceiling dueling. As the clock continues to tick toward the Aug. 2 deadline, specifics from the two very different plans emerged — one offered by House Republicans and the other by Senate Democrats.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
California is the bright spot in enrolling people in the health law's insurance exchanges - beating even the federal Healthcare.gov in how many have signed up. Still, California's enrollment figures - representing about a third of all signups around the nation - mean less than 1 percent of uninsured Californians have signed up for plans.
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
› Verified 8 days ago
| Entity Name | Garden State Healthcare Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700014545 PECOS PAC ID: 8426190687 Enrollment ID: O20100126000693 |
News Archive
A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
President Barack Obama and House Speaker John Boehner each delivered prime time addresses Monday night, capping an extraordinary day of partisan debt-ceiling dueling. As the clock continues to tick toward the Aug. 2 deadline, specifics from the two very different plans emerged — one offered by House Republicans and the other by Senate Democrats.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
California is the bright spot in enrolling people in the health law's insurance exchanges - beating even the federal Healthcare.gov in how many have signed up. Still, California's enrollment figures - representing about a third of all signups around the nation - mean less than 1 percent of uninsured Californians have signed up for plans.
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohammed Y Sandhu, MD 672 Broadway, Bayonne, NJ 07002-4725 Ph: () - | Dr Mohammed Y Sandhu, MD 672 Broadway, Bayonne, NJ 07002-4725 Ph: (201) 339-3710 |
News Archive
A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
President Barack Obama and House Speaker John Boehner each delivered prime time addresses Monday night, capping an extraordinary day of partisan debt-ceiling dueling. As the clock continues to tick toward the Aug. 2 deadline, specifics from the two very different plans emerged — one offered by House Republicans and the other by Senate Democrats.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
California is the bright spot in enrolling people in the health law's insurance exchanges - beating even the federal Healthcare.gov in how many have signed up. Still, California's enrollment figures - representing about a third of all signups around the nation - mean less than 1 percent of uninsured Californians have signed up for plans.
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
› Verified 8 days ago
Dr. George Tarng, MD, MPH Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 744 Broadway, Bayonne, NJ 07002 Phone: 201-436-8888 | |
Deborah M Wozniak, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 19 E 27th St, Bayonne, NJ 07002 Phone: 201-339-1414 Fax: 201-339-5427 | |
Dr. Jack Boghossian, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 631 Broadway, Bayonne, NJ 07002 Phone: 973-364-2682 Fax: 973-364-1430 | |
Danuta Silber, MD PHD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 740 Kennedy Blvd, Bayonne, NJ 07002 Phone: 201-858-0848 Fax: 201-858-1106 | |
Renee Trotter, APN Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Dr. Domonick Condo, Md, 622 Broadway, Bayonne, NJ 07002 Phone: 201-436-2800 | |
Vashti Wanda Ramphal, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 29 E 29th St, Bayonne, NJ 07002 Phone: 201-585-5000 | |
Dr. Dominick Condo, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 622 Broadway, Bayonne, NJ 07002 Phone: 201-436-2800 Fax: 201-436-9840 |